Beta Blocker for Chronic Wound Healing
|ClinicalTrials.gov Identifier: NCT00368602|
Recruitment Status : Terminated (Lack of funding.)
First Posted : August 25, 2006
Last Update Posted : April 7, 2015
|Condition or disease||Intervention/treatment||Phase|
|Ulcer Burns||Drug: Timoptic Other: Placebo||Phase 2|
The purpose of this study is to learn more about how to heal venous leg ulcers faster and to test the safety of a drug and see what effects it has on a venous leg ulcer.
- be interviewed and examined
- have a physical exam
- have blood and urine tested
- have photographs taken of the wound
- apply medication to the leg ulcer as directed
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||40 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Beta Adrenergic Receptor Modulation of Burn Wound Healing|
|Study Start Date :||June 2005|
|Actual Primary Completion Date :||June 2007|
|Actual Study Completion Date :||June 2007|
This group receives topical beta adrenergic antagonists (Timoptic) plus standard of care.
Timoptic to be applied to the target wound daily for up to 12 weeks.
Other Name: beta adrenergic antagonists
Placebo Comparator: 2
The group will be given standard of care with placebo medication.
Saline solution with no active ingredients to be applied to the target wound daily for up to 12 weeks.
- The primary efficacy parameter will be complete ulcer healing, which is defined as 100% epithelialization with no drainage or need for an absorptive dressing. [ Time Frame: 12 weeks ]
- 100% re-epithelialization will be clinically determined at each visit by the Investigator. [ Time Frame: 12 weeks ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00368602
|United States, California|
|VA Medical Center|
|Mather, California, United States, 95655|
|Principal Investigator:||Rivkah R Isseroff, MD||University of California, Davis|